Posted: May 18, 2010

Rosetta Genomics Identifies 49 Novel microRNAs with Potential to Provide Novel Molecular Biomarkers and Drug Target Candidates

(Nanowerk News) Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study entitled "Discovery of microRNAs and other small RNAs in solid tumors" in the online edition of Nucleic Acid Research.
“Our discovery of these new microRNAs gives us direct and exclusive access to 49 novel microRNAs, each one of which has the potential to be, alone or in combination with other microRNAs, a diagnostic biomarker, response biomarker or drug target. In addition, we have filed patent applications on each of these newly discovered microRNAs to enhance our expanding IP portfolio,” stated Kenneth A. Berlin, President and CEO of Rosetta Genomics.
“So far this year, we have had six peer-reviewed articles published on our microRNA technology. These publications are a further demonstration of how Rosetta Genomics is maintaining a leadership position in the development of microRNAs for personalized medicine applications.” The comprehensive database and proprietary technologies we have developed over the years are significant assets that allow us to lead in this area. They enable us to efficiently identify, extract, and quantify microRNAs, and transform them into commercially viable diagnostics, response biomarkers and therapeutics. This unrivaled set of capabilities allows us to harness the power of microRNAs as we work to improve healthcare worldwide,” added Mr. Berlin.
About microRNAs
MicroRNAs (miRNAs) are recently discovered, small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. The unique advantage of microRNAs as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks. It has been suggested that their small size (19 to 21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced. To learn more about microRNAs, please visit
About Rosetta Genomics
Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview™ squamous, miRview™ mets and miRview™ meso, are commercially available through its Philadelphia-based CAP accredited, CLIA-certified lab. Rosetta Genomics is the 2008 winner of the Wall Street Journal’s Technology Innovation Awards in the medical/biotech category.
Source: Rosetta Genomics (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: